Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Cancer Discov. 2021 Nov 9;12(1):62–73. doi: 10.1158/2159-8290.CD-21-1033

Figure 3: Adaptive immune dysfunction in lymphoma patients with recurrent COVID-19 infection.

Figure 3:

a) Multivariate analysis of clinical risk factors predicting re-hospitalization attributable to COVID-19 infection in patients with lymphoma and prior hospitalization attributable to COVID-19. Statistically significant risk factors highlighted in red. b) Kaplan-Meier curve displaying probability of re-hospitalization for COVID-19 in patients with lymphoma based on receipt of anti-CD20 therapy in the year prior to first known documented SARS-CoV-2 PCR positivity. c) Laboratory markers in patients with lymphoma who were either re-admitted or not re-admitted to the hospital for symptomatic COVID-19 infection following discharge from the hospital for acute COVID-19 infection. *p<0.05. **p<0.01.